

CHEMESIS INTERNATIONAL INC.
(the “Company” or “Chemesis”)

**MANAGEMENT DISCUSSION AND ANALYSIS
FOR THE YEARS ENDED JUNE 30, 2020 AND 2019**

This Management Discussion and Analysis (“MD&A”) has been prepared by management in accordance with the requirements of National Instrument 51-102 and should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended June 30, 2020, and the related notes contained therein which have been prepared in accordance with International Financial Reporting Standards (“IFRS”).

All dollar amounts are expressed in Canadian dollars, the reporting currency of the Company, unless otherwise indicated.

DATE

This MD&A is prepared as of October 28, 2020.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This MD&A contains certain forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by and information currently available to the Company. When used in this document, the words “*anticipate*”, “*believe*”, “*estimate*”, “*expect*” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. This MD&A contains forward-looking statements relating to, among other things, regulatory compliance, the sufficiency of current working capital, the estimated cost and availability of funding for the Company’s operations. Such statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or our achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. This MD&A should be read in conjunction with the risk factors described in the *Risk Factors* section of this MD&A. Although the Company has attempted to identify important factors that could cause actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as at the date of the MD&A. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements. The Company does not undertake to update any forward-looking statements except as required by applicable securities laws.

DESCRIPTION OF BUSINESS

Chemesis International Inc. is a vertically integrated company in the cannabis industry focusing on cultivation, manufacturing, distribution and retail. Chemesis currently has operations in California, Puerto Rico, and Colombia.

COVID-19

In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business.

KEY BUSINESS ACTIVITIES

Chemesis International Inc. (formerly Canadian Mining Corp.) was incorporated on April 26, 2013 and was a wholly-owned subsidiary of International Zeolite Corp. Chemesis’ registered records office is 2200 HSBC Building, 885 West Georgia Street, Vancouver BC V6C 3E8. During fiscal 2018, Chemesis was spun out pursuant to a plan of arrangement. On June 5, 2017, Chemesis began trading on the TSX Venture Exchange under the symbol CNG.

On July 17, 2018, Chemesis completed a reverse takeover transaction (“RTO”) with 1145411 BC Ltd. (“1145411”), pursuant to which Chemesis acquired all of the issued and outstanding shares of 1145411 in exchange for 4,680,756 common shares of Chemesis. Accordingly, this transaction was recorded as a reverse acquisition with 1145411 being the acquirer for accounting purposes. The historical assets and liabilities are of 1145411 while the share capital is that of the Company.

Effective July 17, 2018, the Company completed a share consolidation of its share capital on the basis of two existing common shares for one new common share. As a result of the share consolidation, the 32,080,152 common shares issued and outstanding were consolidated to 16,040,076 common shares.

Effective December 20, 2019, the Company completed a share consolidation of its share capital on the basis of ten existing common shares for one new common share. All common shares and per share amounts in the consolidated financial statements and tis MD&A are retroactively presented on a post-share consolidation basis, including the number and exercise price of all share options and warrants.

Pursuant to the RTO, Canadian Mining Corp., under the trading symbol CNG, changed its name to Chemesis International Inc. and de-listed from TSX Venture Exchange and listed its shares on the Canadian Stock Exchange (“CSE”). Chemesis has since changed its business focus from mineral exploration to the continuation of 1145411’s business of pursuing opportunities in the cannabis industry.

On February 1, 2019, the Company and IMC International Mining Corp. (“IMC”) completed a reorganization transaction by way of a plan of arrangement whereby, the Company undertook a reorganization and spin-out of various interests in minerals located in the vicinity of the Harecuvar and Harquahala Mountains, Yavapai County, Arizona to IMC.

On February 1, 2019, Chemesis transferred all of the issued and outstanding common shares of its wholly owned subsidiary, Canadian Mining of Arizona Inc., to IMC. In exchange, the shareholders of Chemesis at the record date received 3,246,625 common shares, 305,000 options and 229,014 warrants of IMC.

Effective December 20, 2019, the Company completed a share consolidation of its share capital on the basis of ten existing common shares for one new common share.

On July 23, 2020, Chemesis started trading its currently listed shares on the CSE under the new symbol “CSI.U” which presented in USD.

Subsidiaries and their activities

1145411 is the owner of 100% of the issued and outstanding capital stock of Bonhomie Labs Inc. (“Bonhomie”), a California corporation. Bonhomie is the owner of 100% of the issued and outstanding capital stock of SAP Global (“SAP”), a California corporation. SAP is the assignee, pursuant to a management agreement of various entitlements that allow it to operate cannabis businesses in the State of California. SAP controls cultivation and manufacturing licenses for its manufacturing facility, where the Company manufactured and distributed medical and recreational THC and CBD products for the California market. During the current year, due to the decline in the market and ongoing repair costs to the facility and surrounding area, the Company decided to terminate its lease and not renew its license for SAP and as a result has impaired all intangible assets, equipment and leasehold improvements previously recognized.

On August 21, 2018 Chemesis acquired 100% of Desert Zen, a state-compliant recreational and medicinal cannabis manufacturing, distribution, and transportation company based in Cathedral City, California. The facility was licensed under state and local laws to manufacture, package, and transport quality cannabis products. During the year ended June 30, 2020, the Company still holds the facility lease and has renewed it’s licenses for Desert Zen, but due in part to the decline in the US market and minimal operations, the Company has decided to recognize an impairment of intangible assets, equipment and leasehold improvements previously recognized.

On November 30, 2018, the Company acquired 80% of Natural Ventures PR LLC (“Natural Ventures”), a cultivation and distribution business located in Puerto Rico. The Natural Ventures has been operational since early 2017 and currently is expanding to meet its growing customer demand. Natural Ventures is licensed to cultivate 100,000 ft² of

cannabis and has 35,000 ft² of manufacturing floor space for quality cannabis products. Natural Ventures has begun growing its own cannabis plants that will be used in manufacturing and distribution of its diverse product line.

On January 11, 2019, the Company acquired 100% of La Finca Interactiva Arachna Inc. SAS (“La Finca”), a hemp and CBD cultivation business located in Colombia. La Finca holds a research and development license in Colombia.

On May 24, 2019, the Company acquired a 60% interest in Kieley Growth Management (“Kieley”), a company with dispensary operations in California, United States. Kieley held a Type-6 Cannabis Processing License as issued by the California Department of Health. During the current year, due in part to the decline in the market and ongoing repair costs to the facility and surrounding area, the Company decided to terminate its lease and not renew its license for Kieley and as a result has impaired all intangible assets, equipment and leasehold improvements previously recognized.

On April 1, 2019 the Company entered into an share exchange agreement to acquire 19.9% equity stake in GSRX Industries Inc. (“GSRX”), a company which owns and operates six cannabis dispensaries and an online ecommerce site. Pursuant to the terms of the acquisition, GSRX issued 11,666,998 common shares to Chemosis. On August 28, 2019, the Company acquired 42,634,124 common shares of GSRX in exchange for 1,488,071 common shares of the Company for a total fair value of \$8,437,358 and acquired 100% of the preferred shares in exchange for 400,000 common shares of the Company with a fair value of \$2,268,000, which were issued in November 2019. Immediately after the transaction, the Company held 67.04% of common share interests in GSRX. The acquisition of GSRX was accounted for as a business combination. In addition, on August 28, 2020, Chemosis placed three out of the five board seats on the Board of Directors of GSRX and continues to hold approximately 66% of the outstanding shares of GSRX.

Key license agreements

SAP Brand rights

On July 20, 2018, the Company issued 66,464 common shares for a fair value of \$255,886 pursuant to an acquisition of licensed rights from SAP. Further, the Company paid \$110,000 cash. Such rights included, the brand name, trade name, and trademarks together with all of the patents, patent applications, and inventions. These licenses were amortized over the estimated useful life of 5 years. The Company wrote off the balance of the licenses and recognized as impaired during the year ended June 30, 2020, as the license is no longer in use.

Rapid Dose Therapeutics Inc. (“RDT”)

On October 12, 2018, the Company acquired the license rights from RDT, a Canadian bio-technology company which provides proprietary drug delivery technologies. RDT’s QuickStrip is an oral fast-dissolving drug delivery system. Under the terms of the agreement, the Company received rights to produce, distribute, and sell QuickStrip products, with rights for cannabis markets in California. Total consideration was \$318,010, paid by \$130,570 in cash and 17,356 common shares for a total share fair value of \$187,440. This license is amortized over the estimated useful life of 5 years. Due to a declining market in the California, the Company has written off the balance of the license during the year ended June 30, 2020.

Kieley Growth Management License

On May 24, 2019, the Company acquired a 60% interest in Kieley, who held a Type-6 Cannabis Processing License as issued by the California Department of Health. This license had a value of \$404,040 and was amortized over one year. Due to a declining market in the California, the Company has written off the balance of the license during the year ended June 30, 2020.

Natural Ventures License

On November 9, 2018, the Company acquired Natural Ventures. At the time, Natural Ventures held a cultivation license and a cannabis manufacturing license. These licenses were measured at a fair value of \$1,662,625 and were amortized over 1 year to reflect the annual license renewal period. The Company’s licenses continue to be active and renewed annually.

Desert Zen License

On August 10, 2018, the Company acquired Desert Zen, who held a light manufacturing (Type-P) license and distributor (Type-11) license issued by the California Department of Health. The license had a fair value of \$230,000 on acquisition and was amortized over one year. Due to a declining market in California during the year ended June

30, 2020, the Company wrote off the balance of the license; however, the Company continues to maintain this license annually.

La Finca License

La Finca holds seed producer and hemp cultivation licenses in Colombia (the “La Finca Licenses”) with a fair value of \$100,000. The Company notes that the La Finca Licenses permit La Finca to do the following with respect to non-psychoactive cannabis: (1) production of seeds and cultivation of cannabis plants; (2) fabrication of derivatives; (3) storage, transportation and distribution of products; and (4) use and possession for industrial and scientific purposes. The La Finca Licenses also enable La Finca to commercially sell biomass and cosmetic finished products. The Company also notes that the La Finca Licenses remain up to date and valid. However, in order to carry out further product commercialization and the exportation of such products under the La Finca Licenses, there are certain certifications and registrations that must be obtained. For instance, in order to further commercialize, it is first necessary to complete the Pruebas de Evaluacion Agronomica - Agronomic Evaluation Trials (“PEAs”) and obtain a registered cultivar certification from the Government of the Republic of Colombia. The PEA process (“PEA Process”) includes multiple stages, including development of seeds through a growth cycle in various regions throughout Colombia followed by rigorous testing of the performance and potency of the plants. The PEA Process requires significant capital investment and typically takes approximately 12-18 months to complete, depending on the success of the cultivation and harvest process and the speed of regulatory approvals. As such, while the Company is currently engaged in the PEA Process, under Colombian regulations related to cannabis matters, La Finca does not require additional licenses other than the ones it currently has for the production and marketing of finished products or non-psychoactive cannabis-based raw materials. On April 27, 2020, the Company announced its intention to spin-out the assets of La Finca to be able to focus in on the specific needs of this entity and maximize its ability to meet its goals within Latin America.

Patents

The Company’s subsidiary, GSRX, applied for patents which it believes are a new, original and ornamental design for Oral Consumable Flakes. The patents use the methods of preparing soluble encapsulated plant-based compositions. The fair value of the patent application costs was determined to be \$nil on the acquisition date of GSRX.

Below is a summary of all licenses by location, entity holding the license, renewal date, and status of the license:

Entity which holds the license	Type of License	Renewal date (annual)	Status of License
PUERTO RICO			
Natural Ventures	Manufacturing	November 16, 2020	Active
Natural Ventures	Cultivation	November 16, 2020	Active
Caribbean Green	Dispensary	December 28, 2020	Active
Caribbean Green	Dispensary	February 6, 2021	Active
Caribbean Green	Dispensary	June 29, 2021	Active
Project 1493, LLC (wholly-owned subsidiary of GSRX)	Dispensary	October 1, 2021	Active
Project 1493, LLC (wholly-owned subsidiary of GSRX)	Dispensary	December 21, 2020	Active
Project 1493, LLC (wholly-owned subsidiary of GSRX)	Dispensary	May 29, 2021	Active
Project 1493, LLC (wholly-owned subsidiary of GSRX)	Dispensary	May 29, 2021	Active
Project 1493, LLC (wholly-owned subsidiary of GSRX)	Dispensary	March 26, 2021	Active
CALIFORNIA			

Desert Zen	Distribution	June 27, 2021	Active
Desert Zen	Manufacturing	March 28, 2021	Active
SAP Global Licensing	Manufacturing	April 26, 2020	No longer active – the Company will not be renewing
Kieley Growth	Manufacturing	June 5, 2020	No longer active – the Company will not be renewing
Green Spirit Mendocino, LLC	Dispensary	April 4, 2021	Active
Point Arena Distribution, LLC	Distribution	June 27, 2021	Active
Point Arena Manufacturing, LLC	Manufacturing	May 15, 2021	Active
Colombia			
La Finca Interactiva Arachna Med SAS	cultivation of non-psychoactive plants license (cultivation and manufacturing)	October 19, 2022	Active
La Finca Interactiva Arachna Med SAS	seed producer certificate (cultivation and manufacturing)	N/A	Active
La Finca Interactiva Arachna Med SAS	commercial cultivar certificate	pending	pending
La Finca Interactiva Arachna Med SAS	commercial cultivar certificate	pending	pending
La Finca Interactiva Arachna Med SAS	commercial cultivar certificate	pending	pending

Chemesis no longer actively holds exclusive rights to cultivation hemp licenses in Puerto Rico.

Business acquisitions

Bonhomie / SAP Global

During the year ended June 30, 2018, the Company acquired 100% of the issued and outstanding shares of Bonhomie for \$100. At the time, Bonhomie held a 51% controlling interest in SAP. At the date of the Company’s acquisition of Bonhomie, the net assets were acquired in exchange for the Company settling the liabilities related to the assets acquired. Accordingly, at the date of the Company’s acquisition of Bonhomie, SAP was considered to have net identifiable assets of \$574,028. On July 19, 2018, the Company increased its ownership in SAP from 51% to 80% for no additional consideration. On July 3, 2019, the Company increased its holdings to 100% of the issued and outstanding capital stock of SAP by issuing 100,000 common shares of the Company with a fair value of \$1,780,000.

Desert Zen

On August 10, 2018, the Company acquired 100% of the shares of Desert Zen for USD\$200,000 cash paid upon closing, as well as 65,250 common shares of the Company with a fair value of \$342,563 escrowed over 36 months. This transaction was accounted for as a business combination, as such the Company used the acquisition method of accounting. The consideration paid in excess of the net assets of the acquired business was \$374,830 and recognized in goodwill, which was written down to \$nil during the year ended June 30, 2020 due to a decline in the US market.

Natural Ventures

On November 30, 2018, the Company acquired 80% of Natural Ventures for cash payment of USD\$2,800,000 and 223,525 common shares of the company with a fair value of \$1,877,607 escrowed over 36 months. This transaction was accounted for as a business combination, as such the Company used the acquisition method of accounting. The consideration paid in excess of the net assets of the acquired business was \$3,557,713 and was recognized in goodwill. The license is amortized over a useful life of 1 year.

La Finca

On January 11, 2019, the Company acquired 100% of La Finca. The Company acquired a promissory note of \$5,500,000 and issued 748,000 common shares with a fair value of \$7,225,680 escrowed over 36 months. This transaction was accounted for as an asset acquisition. The consideration paid in excess of the net assets of the acquired assets was \$10,305,740 attributable to seed research, development and technology expenditures for the year ended June 30, 2019.

Kieley Growth Management

On May 24, 2019, the Company acquired a 60% interest in Kieley. The Company acquired a non-interest-bearing promissory note of USD \$1,000,000 and issued 67,231 common shares with a fair value of \$880,058 as consideration for 60% of Kieley's common shares. This transaction was accounted for as a business combination, as such the Company used the acquisition method of accounting. The consideration paid in excess of the net assets of the acquired business was \$2,259,080 and is recognized in goodwill, which was written down to \$nil during the year ended June 30, 2020 due to a decline in the US market.

GSRX Industries Inc.

On April 1, 2019, the Company entered into an agreement to acquire 19.9% equity stake in GSRX Industries Inc. Pursuant to the terms of the acquisition, GSRX issued 11,666,998 common shares to Chemosis. GSRX has also granted a pre-emptive right to maintain such ownership percentage. In exchange, the Company issued 729,187 common shares, which are subject to hold periods of up to 36 months. At the time of acquisition, the Company had no board members or management on the Board of Directors of GSRX. On August 28, 2019, the Company acquired 42,634,124 common shares of GSRX in exchange for 1,488,071 common shares of the Company for a total fair value of \$8,437,358 and acquired a 100% of the preferred shares in exchange for 400,000 common shares of the Company with an fair value of \$2,268,000. Immediately after the transaction the Company held a 67.04 % common share interest and in GSRX. In connection with the acquisition, the Company acquired 100% of the preferred shares in exchange for 400,000 common shares of the Company (Notes 5 and 9) and has three board seats on the Board of Directors of GSRX.

TRANSACTIONS IN PROGRESS

On September 9, 2019 the Company announced it had entered into an agreement to purchase three cannabis dispensary operations in Puerto Rico from Caribbean Green LLC ("**Caribbean Green**") in exchange for USD \$1.2 million in cash over 24 months. The Company concurrently entered into a services agreement with Caribbean Green which permits the Company to operate the three cannabis dispensaries until the transfer of licenses, material leases, contracts and other agreements into the name of Natural Ventures are approved by the Puerto Rico Department of Health. Until such time, there is uncertainty as to whether the Puerto Rican regulators will allow such transfer and registration. The management of the Company has concluded that until the licenses, material leases, contracts and other agreements have been assigned, transferred to and registered in the name of Natural Ventures, the Company is an investor in Caribbean Green and does not control the three cannabis dispensaries in substance under IFRS 3 and IFRS 10 and does not have unequivocal and exclusive rights to the risks and rewards of business until such time. As at June 30, 2020, the Company has paid USD \$450,000 and is included in deposits subject to the completion of the license transfer.

OVERALL PERFORMANCE

The net assets of the Company decreased from \$23,322,636 at June 30, 2019 to \$11,837,362 at June 30, 2020. The most significant assets at June 30, 2020 include: cash of \$1,044,585 (June 30, 2019 - \$641,583), inventory of \$1,129,131 (June 30, 2019 - \$830,001), biological assets of \$1,842,848 (June 30, 2019 - \$1,244,938), amounts receivable of \$752,668 (June 30, 2019 - \$2,392,559), fixed assets of \$4,249,892 (June 30, 2019 - \$7,057,515), intangible assets of \$2,051,774 (June 30, 2019 - \$2,541,942), deposits of \$1,033,234 (June 30, 2019 - \$26,743), right of use assets of \$2,916,092 (June 30, 2019 - \$nil), and goodwill of \$7,334,212 (June 30, 2019 - \$4,390,323).

The Company's primary liabilities at June 30, 2020 consisted of accounts payable and accrued liabilities of \$6,051,158 (June 30, 2019 - \$2,488,824), current portion of lease liabilities of \$1,313,386 (June 30, 2019 - \$nil), lease liabilities of \$2,097,156 (June 30, 2019 - \$nil), and convertible debt of \$1,063,562 (June 30, 2019 - \$nil).

Cash increased by \$403,002 pursuant to financing activities which raised \$5,409,108, investing activities providing \$1,457,169, both of which are offset by cash used in operating activities of \$5,865,034.

HIGHLIGHTS

On July 2, 2019, the Company's subsidiary, Natural Ventures, signed a USD \$6,000,000 annual purchase order with PR ONE, a Puerto Rico based medical cannabis company, to supply dry flower and cannabis infused goods. Natural Ventures also signed an exclusive manufacturing agreement with PR ONE with a three-year term with the initial order to be delivered in calendar Q4 of 2019. In connection with this transaction, PR One extended Natural Ventures a line of credit of USD\$500,000 at 5% interest per annum. The Company notes that this agreement and line of credit was terminated during the year due to the effect of the temporary restriction on licensed activities pursuant to the administrative review over NVPR's licenses.

On July 15, 2019, the Company secured a USD \$4,000,000 purchase order to manufacture and distribute Happy Tea, a US based CBD tea company, products and additional SKUs. The Company notes that Happy Tea has not been able to fulfil the obligation under the purchase order, and as such, the Company has paused this transaction until further notice.

On August 12, 2019, the Company announced that it will begin to manufacture, package, and distribute its own line of tobacco-free smokeless cannabis and hemp derived chew with initial launch and commercialization in the US, Puerto Rico, and Canada. The Company has yet to move into this market and instead has focused all of its efforts into the cannabis space.

On August 19, 2019, the Company announced it is in the process of obtaining NSF Certification for its facility to ensure the Company is able to market its products to consumers with NSF accreditation. The certification will allow the Company to manufacture its tobacco-free chew products under global GMP standards. The Company decided to stop forward momentum towards tobacco-free chew products and did not obtain NFS Certification for its facility.

On August 26, 2019, the Company received an initial purchase order for USD \$1,100,000 with a United Kingdom based distributor to manufacture CBD products. The products will be manufactured in the Company's California based manufacturing facility. A number of factors, including the increase in competition in the CBD space, decline in the capital markets leading to reduced access to favorable capital and administrative review, the Company did not pursue this business venture.

On August 28, 2019, the Company completed the acquisition of a controlling interest in GSRX Industries Inc. of 67% of its outstanding common shares. The GSRX Board of Directors consists of 5 persons, of which the Company appointed three. In addition, the Company also completed a non-brokered private placement for total proceeds of \$1,400,000.

On September 9, 2019, the Company's subsidiary, Natural Ventures, through a partnership with First Medical Cannabis LLC, received one of the first hemp cultivation and processing licenses in Puerto Rico.

On September 11, 2019, the Company entered into an agreement to purchase three cannabis dispensary operation in Puerto Rico from Caribbean Green LLC in exchange for USD \$1.2 million in cash over 24 months.

On September 24, 2019, the Company appointed Josh Rosenberg to its Board of Directors. Mr. Rosenberg was granted 250,000 stock options under the terms of the Company's share-based compensation plan. Mr. Deepak Anand resigned from the Board of Directors.

On October 23, 2019, the Company, as well as other companies operating in Puerto Rico, had certain cannabis licenses held by its subsidiary, Natural Ventures, subjected to an administrative review by the Puerto Rico Department of Health (the "Review").

On November 1, 2019 the Company provided a corporate update on the previously announced Review. At the time, the Company continued to work with the Puerto Rico Department of Health regarding the Review. The Company noted that at the time, the licenses were effectively in abeyance and that only certain activities were permitted to be carried out for the purpose of preserving and maintaining inventory.

On December 20, 2019, the Company completed a consolidation on the basis of ten new common shares for one old common share. After the share consolidation, the number of shares outstanding were 11,498,813.

On January 14, 2020, the Company announced that it was granting 2,295,000 stock options at an exercise price of \$0.90 for a period of 60 months to directors, officers and consultants.

On January 17, 2020, the Company received news that the abeyance of the Company's licenses held in Puerto Rico by the Puerto Rico Department, as a result of the Review, was held as unconstitutional by the Puerto Rico Superior Court (San Juan) (the "Decision"), subject to a 30-day appeal deadline. The Company's licenses held in Puerto Rico were reinstated on February 3, 2020.

On January 23, 2020, the Company closed a private placement of 13,506,030 units of the Company at price of \$0.370 per unit (the "Units") for total proceeds of \$5,000,000. Each Unit is comprised of one common share and one common share purchase warrant, which is exercisable for one common share at a price of \$0.405 for a period of 24 months. Of the total proceeds:

- i) 3,742,807 units were issued to settle \$1,141,556 owed under a convertible debt held by a director of the Company and 1,128,771 units were issued to settle \$344,275 of other convertible debentures (Note 12);
- ii) 239,742 in accounts payable owing to a director of the Company was settled with 786,039 units; and
- iii) The balance of \$3,274,427 was received in cash.

The Company also settled and discharged an aggregate total indebtedness of \$399,135, on the following basis:

- i) \$284,444 owed under a convertible debenture repaid through the issuance of 406,348 units of the Company (the "Debt Settlement Units"), with each Debt Settlement Unit being comprised of one common share and one common share purchase warrant (the "Debt Settlement Warrants"). Each Debt Settlement Warrant is exercisable for one common share at a price of \$0.70 for a period of 24 months; and
- ii) \$114,691 owed to a creditor was settled through the issuance of 163,844 Debt Settlement Units.

In addition, on January 23, 2020, the Company completed a convertible debt settlement whereby it discharged a total indebtedness of \$1,109,440 under certain convertible debentures through the issuance of 1,232,711 units of the Company (the "Debt Conversion Units"), with each Debt Conversion Unit being comprised of one common share and one common share purchase warrant (the "Debt Conversion Warrants"). Each Debt Conversion Warrant is exercisable for one common share at a price of \$1.12 for a period of 24 months.

On January 27, 2020, the Puerto Rico Department of Health commenced an appeal in respect the Decision.

On March 10, 2020, the Company effected a change to the Board of Directors of GSRX, such that Messrs. Leslie Ball, Christian Briggs, and Steven Farkhas were removed as directors of GSRX; and Messrs. Troy Nihart and Jeff Rogers were appointed to the GSRX Board.

On April 13, 2020, the Company appointed Mr. Josh Rosenberg as President of the Company.

On April 27, 2020, the Company entered an arrangement agreement pursuant to which the Company will spin out La Finca into a wholly-owned subsidiary of the Company, 1247262 B.C. Ltd. through a plan of arrangement under the *Business Corporations Act* (British Columbia) (the "Arrangement"). Upon completion of the Arrangement, La Finca will become a wholly-owned subsidiary of 1247262 B.C. Ltd.

On May 8, 2020, the Company's subsidiary, Natural Ventures, has entered into an option agreement (the "Option Agreement") with GSRX, pursuant to which GSRX granted an option to Natural Ventures to acquire 100% of the issued and outstanding membership interest of GSRX's wholly-owned subsidiary, Project 1493, LLC, which holds all of GSRX's Puerto Rican dispensaries. No progress has been made towards this option agreement.

On May 19, 2020, the Company closed the first tranche of a non-brokered private placement issuing an aggregate of 1,420,000 units at a price of \$0.50 per unit for gross proceeds of \$710,000. The private placement is part of a larger

offering of up to 6,000,000 units. Each unit consisted of one common share of the Company and one common share purchase warrant entitling the holder to purchase one additional common share at an exercise price of \$1.00 for a period of 24 months.

On May 20, 2020, the Company closed the second tranche of a non-brokered private placement issuing an aggregate of 1,272,500 units at a price of \$0.50 per unit for gross proceeds of \$636,250. The private placement is part of a larger offering of up to 6,000,000. Each unit consisted of one common share of the Company and one common share purchase warrant entitling the holder to purchase one additional common share at an exercise price of \$1.00 for a period of 24 months.

On June 1, 2020, the Company entered in to an exclusive partnership with Via-Touch Media for its VICKI IoT self-checkout solution for retail, pursuant to which the Company acquired exclusive rights across North America for VICKI machines containing cannabis products. Subsequent to year end, the Company has placed a vending machine in the Atlanta airport and has begun to see positive results.

On June 17, 2020, as a result of a review by the British Columbia Securities Commission, Chemesis provided clarification and summary of certain of its disclosure with respect to the status of the cannabis licenses it holds in Puerto Rico, including licenses held by its subsidiary, Natural Ventures and which the Company indirectly acquired through its acquisition of the majority of the voting shares and rights of GSRX.

On July 8, 2020, the Company closed a final tranche of a private placement for 5,235,300 units at a price of \$0.50 per unit for gross proceeds totaling \$2,617,650. Each unit is comprised one common share and one common share purchase warrant with each warrant entitling the holder to purchase one additional common share at an exercise price of \$1.00 for a period of 24 months. The Company settled payable liabilities of an aggregate of CAD\$671,800 and USD \$24,000 through the issuance of 692,416 units and 38,307 common shares respectively.

On July 13, 2020, the Company filed a preliminary Form 1-A Regulation A, Tier 2 Offering Statement under the United States Securities Act of 1933, as amended, with the United States Securities and Exchange Commission in connection with the Company's intention to offer up to 40,000,000 units at a price of USD \$0.50 per unit. Each unit would be comprised of one common share of the Company and one common share purchase warrant with each warrant entitling the holder to purchase one additional common share at an exercise price of USD \$0.75 for a period of 24 months.

On July 23, 2020, the Company commenced trading on the CSE in USD under the new symbol CSI.U.

On July 24, 2020, the Company completed a debt settlement in the amount of \$470,843, which was satisfied through the issuance of 692,416 units at a price of \$0.68 per unit. Each unit is comprised of one common share and one common share purchase warrant at a exercise price of \$0.85 for a period of 24 months. The Company also settled further outstanding debt in the amount of USD \$24,000 through the issuance of 38,307 common shares at a price of \$0.85 per common share.

On August 7, 2020, the Company announced that the Puerto Rico Court of Appeals ruled in favour of the Puerto Rico Medicinal Cannabis Office, a constituent of Puerto Rico's Department of Health, in regard to the Puerto Rico cannabis licenses held by the Company's subsidiaries Natural Ventures PR, LLC and GSRX Industries Inc (the "Appeal Decision"). The Appeal Decision reverses the Decision, wherein it was found that the abeyance of the Licenses was invalid and unconstitutional and that such action was nullified. The Company notes that the Appeal Decision does not entail an automatic abeyance of the Company's licenses held in Puerto Rico and in fact operations under such licenses are continuing in the ordinary course. The Company further notes that the Court of Appeals based its decision on procedural grounds, finding that the Court of First Instance did not have jurisdiction over the matter; the Court of Appeal did not decide upon substantive merits.

On September 2, 2020, the Company announced that the Puerto Rico cannabis licenses held by the Company's subsidiary, Natural Ventures, have been granted an administrative extension for a period of sixty days by the Department of Health of Puerto Rico.

On September 28, 2020, the Company announced that the Department of Health of Puerto Rico is conducting a review of certain filings made by the Company's subsidiaries, Natural Ventures and GSRX with the Department of Health. This review is in addition to the ongoing Review by the Department of Health.

DISCUSSION OF OPERATIONS

The following highlights the key operating expenditures during the year ended June 30, 2020 compared to the year ended June 30, 2019:

For the year ended June 30, 2020 compared to the year ended June 30, 2019

During the year ended June 30, 2020, the Company incurred a net loss of \$38,618,477 (June 30, 2019 - \$39,705,854). The net loss for the year ended June 30, 2020 consists primarily of the following:

- Gross profit of \$5,650,853 (June 30, 2019 - \$2,086,985) consists primarily of net revenues generated from increased gross margins due to moving away from low margin bulk CBD sales and now only generating revenues from cultivation, manufacturing and retail sales.
- Advertising and marketing of \$1,792,313 (June 30, 2019 - \$4,233,999) consists of advertising and marketing campaigns to increase market awareness and brand generation activities. The Company spent less on advertising and marketing campaigns in the year to conserve cash flows.
- Consulting and payroll of \$3,474,567 (June 30, 2019 - \$1,964,939) consists primarily of services used in operational activities of its California and Puerto Rico subsidiaries which increased significantly due to the acquisition of GSRX.
- Management fees of \$728,265 (June 30, 2019 - \$424,473) consists primarily of services used in corporate activities and reflects the changing needs of the Company as it continues evaluating the expansion of its offerings in the cannabis market throughout the US, Puerto Rico, and Colombia. The increase is due to increased compensation and addition of new management.
- Office and miscellaneous expense of \$4,020,462 (June 30, 2019 - \$1,170,537) consists of all costs associated with running the 5-operating retail locations in Puerto Rico and its cultivation and manufacturing. The increase is primarily due to the addition of GSRX's operations..
- Professional fees of \$2,951,081 (June 30, 2019 - \$1,540,524) consists primarily of the fees incurred for general corporate matters and to complete significant acquisition transactions. The increase is associated with addressing regulatory inquiry and maintenance of our licenses.
- Share based payments of \$3,569,588 (June 30, 2019 - \$4,539,342) consists primarily of the non-cash fair value as measured by the Black-Sholes option pricing model to reflect the grant of 2,295,000 options and 2,500,000 restricted share units ("RSU") during the year ended June 30, 2020.
- Depreciation of \$3,811,749 (June 30, 2019 - \$983,245) consists primarily of the non-cash reduction in the value of the Company's fixed assets over their useful lives and amortization of the GSRX intangible assets. The increase is due to the amortization of the GSRX intangible assets.
- Interest expense of \$1,581,183 (June 30, 2019 - \$599,522) consists of the accretion of the newly adopted accounting treatment for rental leases as lease liabilities and the amortization of the debt component of convertible debt. The increase over the prior year is due to the increase in amortization of convertible debt and the increase in the number of leases due to GSRX acquisition and the related accretion expense.
- Loss on investment in GSRX of \$9,839,396 (June 30, 2019 - \$2,646,285) consists primarily of the non-cash fair value adjustment of GSRX shares measured up to the date of acquisition of control on August 28, 2019. This investment is now being consolidated pursuant to a business combination.
- Change in fair value of derivative liabilities of \$3,773,450 (June 30, 2019 - \$(1,380,694)) consists primarily of a non-cash fair value adjustment to the value of derivative liabilities to \$nil as a result of the conversion feature being out of the money.

- Loss on debt settlement of \$(4,248,086) (June 30, 2019 - \$(292,629)) consists primarily of the difference between the amortized value of convertible debt compared to the fair value of shares issued to settled debt.
- Impairment of \$9,991,891 (June 30 - \$2,438,359) was primarily due to asset write-downs associated with abandonment of SAP leasehold improvements, the abandonment of patent costs, and goodwill write-down following the decline in the California market.

During the year ended June 30, 2020, the Company incurred a comprehensive net loss of \$38,977,977 (June 30, 2019 - \$38,974,135). The difference from net loss arises on a foreign currency translation adjustment of \$(379,500) (June 30, 2019 - \$731,719) arising from non-cash presentation currency adjustment of its US, Puerto Rico and Colombian subsidiaries' financial information to Canadian dollars.

SUMMARY OF QUARTERLY RESULTS

The following is a summary of the Company's financial results for the eight most recently completed interim quarters:

	Quarter Ended June 30, 2020 \$	Quarter Ended March 31, 2020 \$	Quarter Ended December 31, 2019 \$	Quarter Ended September 30, 2019 \$
Revenue	3,919,025	4,529,524	944,457	4,700,834
Operating Expense	(7,026,208)	(5,574,102)	(6,485,451)	(3,085,273)
Net loss	(6,599,348)	(11,003,732)	(18,636,519)	(2,378,878)
Comprehensive income (loss)	(18,722,907)	1,040,904	(18,606,165)	(2,709,809)
Basic and diluted loss per share, basic and diluted	(0.99)	(0.44)	(1.78)	(0.20)

	Quarter Ended June 30, 2019 \$	Quarter Ended March 31, 2019 \$	Quarter Ended December 31, 2018 \$	Quarter Ended September 30, 2018 \$
Revenue	4,051,471	3,406,413	2,820,105	1,238,835
Operating Expense	(6,598,168)	(3,778,789)	(2,320,033)	(3,626,506)
Net loss	(19,028,079)	(3,133,856)	(2,335,980)	(11,379,138)
Comprehensive loss	(18,189,590)	(3,844,309)	(1,757,355)	(11,354,080)
Basic and diluted loss per share, basic and diluted	(2.30)	(0.40)	(0.36)	(2.00)

On a quarter-by-quarter basis the loss can fluctuate significantly due to a number of factors including first year of operations of a start-up cannabis Company, timing of stock option grants, changes in nature of the business and significant one-time transactions.

An analysis of the quarterly results over the quarters shows a significant change in financial performance primarily due to the completion of the RTO and activities to go from a start-up to a listed public company with revenues. In the quarter ended September 30, 2018, the Company completed an RTO transaction with Chemesis and 1145411 BC Ltd. as a result, became the continuing entity. Listing acquisition expense for period was \$7,218,093. The Company also issued stock-options with a fair value of \$2,243,580 in that period. The Company began earning revenues on sale of cannabis related products of \$1,238,835. In the quarter ending December 31, 2018, the Company continued earning revenues on sale of cannabis related products of \$2,820,105, acquired Natural Ventures and a number of licenses. In the quarter ending March 31, 2019, the Company had increased revenues to \$3,406,413 with increased activities from Natural Ventures and US operations. In the quarter ended June 30, 2019, the Company earned revenues of \$4,051,471 with the quarter seeing increased activity and sales from previous quarters. In the quarter ended September 30, 2019,

the Company earned revenues of \$4,700,834. In the quarter ended December 31, 2019, the Company earned revenues of \$944,457 following the Review of some of the Company's licenses in Puerto Rico and the decline of the California market. In the quarter ended March 31, 2020, the Company's licenses in Puerto Rico were reinstated and the Company was deemed an essential service in Puerto Rico. This resulted in a recovery in revenues and operational activities resulting in revenues of \$4,529,524. In the quarter ended June 30, 2020, the Company earned revenues of \$3,919,025. The Company expects to see revenues increase going forward as the Company's retail stores continue to ramp up and begin producing at capacity now that the Company's licenses have been reinstated.

SELECTED ANNUAL INFORMATION

The following selected annual financial information is derived from the audited consolidated financial statements for the three most recently completed financial years summarized as follows:

Years ended	2020 \$	2019 \$	2018 \$
Revenues	14,093,840	9,311,119	Nil
Gross profit	5,650,853	2,086,985	Nil
Net earnings (loss)	(38,618,477)	(39,705,854)	(665,444)
Total assets	22,439,598	33,723,059	3,416,885
Shareholder's equity	11,837,362	22,322,636	3,210,243
Loss per share	(1.95)	(0.50)	(6,143)

SEGMENTED REPORTING

The Company currently has four operating segments and generates external revenues from the sale of cannabis products. The operating segments have been disclosed by geographical region as follows:

	Assets \$	Liabilities \$	Revenues \$	Depreciation \$	Interest \$	Income tax recovery \$	Profit (loss) \$
Canada	436,918	3,102,285	-	2,115,792	1,106,987	-	(27,835,251)
United States - California							
<i>Manufacturing</i>	-	454,420	605,385	548,745	35,610	(56,026)	(6,227,825)
<i>Bulk CBD</i>	-	-	-	-	-	-	-
United States - Puerto Rico							
<i>Cultivation and manufacturing</i>	8,762,931	4,195,026	2,385,210	96,614	128,490	-	(2,050,377)
<i>Retail/dispensary</i>	13,081,326	2,607,689	11,103,245	908,597	270,697	-	(2,088,191)
Colombia	158,423	242,818	-	142,001	39,399	-	(416,833)
	22,439,598	10,602,238	14,093,840	3,811,749	1,581,183	(56,026)	(38,618,477)

Revenues earned in California consist of \$5,491 of oils and extracts and \$418,999 in bulk product sales. Sales generated in Puerto Rico consist of \$367,331 in sales from cultivation, \$1,542,516 in sales from manufacturing and \$7,840,478 from retail. The Company's revenues are now primarily earned in Puerto Rico which ranges in profit margin from 30%-40% depending on the availability and related cost of supply of cannabis product. The Company has moved away from bulk CBD transactions for the time being which yielded lower margins (10%-20% range).

LIQUIDITY AND CAPITAL RESOURCES

As at June 30, 2020, the Company had cash of \$1,044,585, inventory of \$1,129,131, biological assets of \$1,842,848 and \$752,668 in amounts receivable. The Company has working capital deficit of \$3,650,686 (June 30, 2019 – \$204,230).

During the year ended June 30, 2020:

- The Company received cash of \$140,000 pursuant to the exercise of options and warrants;
- The Company received cash of \$1,455,080 pursuant to convertible debentures converted;

- c. The Company received net cash of \$5,246,177 pursuant to private placements completed; and
- d. The Company received \$22,500 for subscriptions for common shares not yet issued.

The Company has access to additional equity financing agreement for up to \$25,000,000, with Alumina Partners, LLC, a New York-based private equity firm that has made substantial investments in the cannabis space. The agreement details the purchase of up to \$25,000,000 of units of the Company, consisting of one common share and one common share purchase warrant, at discounts ranging from 15% to 25% of the market price of the Company's shares, subject to the rules and policies of the CSE, with each equity financing occurring exclusively at the option of the Company, throughout the 24-month term of the agreement. The Company has used \$750,000 of this lending facility to date.

Additionally, the Company has entered into a \$10,000,000 share subscription agreement with Global Emerging Markets ("GEM"). The agreement provides that the Company may, at any time while the agreement is in effect, deliver a draw-down notice to GEM specify the number of common shares for which GEM will then have an obligation to subscribe up to a maximum of \$10,000,000. As of June 30, 2020, the Company has drawn down \$778,000 on this equity financing arrangement.

If additional funds are required, the Company plans to raise capital primarily through the private placement of its equity securities. Under such circumstances, there is no assurance that the Company will be able to obtain further funds required for the Company's continued working capital requirements.

Operating Activities

The Company used net cash of \$5,865,034 in operating activities during the year ended June 30, 2020.

Investing Activities

The Company received cash of \$1,457,169 in investing activities during the year ended June 30, 2020. Investing activities primarily consisted of cash received pursuant to acquisition of GSRX of \$2,026,139, proceeds on sale of a building of \$1,224,779, offset by purchase of equipment and leaseholds, and deposits on acquisition of licenses of \$614,565.

Financing Activities

The Company received cash of \$5,409,108 from financing activities during the year ended June 30, 2020. Financing activities primarily consisted of cash of \$140,000 received pursuant to the exercise of options and warrants, cash of \$22,500 received pursuant to subscriptions, net cash of \$5,246,177 received from private placements, cash received from the conversion of convertible debentures of \$1,455,080, offset by lease payments made of \$1,454,649.

CHANGES IN ACCOUNTING POLICIES

With the exception of the recently adopted accounting policies, the management discussion and analysis has been prepared on the basis of accounting policies and methods of computation consistent with those applied in the Company's audited annual financial statement for the fiscal year ended June 30, 2020, filed October 28, 2020.

Accounting standards adopted during the period

Certain new standards, interpretations and amendments to existing standards have been issued by the IASB or International Financial Reporting Interpretations Committee ("IFRIC") that are mandatory for accounting periods beginning after January 1, 2019, or later periods. New standards and updates, which are not applicable or are not consequential to the Company, have been excluded from the list below.

IFRIC 23 Uncertainty over income tax treatments - clarifies the application of recognition and measurement requirement in IAS 12, Income Taxes, when there is uncertainty over income tax treatments. It specifically addresses whether an entity considers each tax treatment independently or collectively, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax credits and tax rates, and how an entity considers changes in facts and circumstances. IFRIC 23 is effective

for the Company's current annual period retrospectively and the adoption did not have a significant impact on the Company's consolidated financial statements for the year ended June 30, 2020.

The Company adopted the requirements of IFRS 16 *Leases* effective July 1, 2019. This new standard replaces IAS 17 *Leases* and the related interpretative guidance. IFRS 16 applies a control model to the identification of leases, distinguishing between a lease and a service contract on the basis of whether the customer controls the asset being leased. For those assets determined to meet the definition of a lease, IFRS 16 introduces significant changes to the accounting by lessees, introducing a single, on-balance sheet accounting model that is similar to the current accounting for finance leases, with limited exceptions for short-term leases or leases of low value assets. Lessor accounting is substantially changed.

On adoption, the Company transitioned to the new standard using the modified retrospective approach and:

- a) Measured the lease liabilities based on the present value of the remaining lease payments discounted using the Company's incremental borrowing rate of at July 1, 2019;
- b) Measured the right-of-use assets as if IFRS 16 had been applied since the commencement date, but discounted using the Company's incremental borrowing rate at July 1, 2019; and
- c) Recording the cumulative difference to deficit;

The net impact on deficit on July 1, 2019 was a \$nil.

The following is a reconciliation of total operating lease commitments at June 30, 2019, to the lease liabilities recognized at July 1, 2019:

Lease liabilities before discounting	\$ 3,268,752
Discounted using incremental borrowing rate of 15%	(664,897)
Operating lease liabilities	\$ 2,603,855

For any new contracts entered into on or after July 1, 2019, the Company considers whether a contract is, or contains a lease. A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'. To apply this definition the Company assesses whether the contract meets six key evaluations, amongst which are:

- a) The contract contains an identified asset, which is either explicitly identified in the contract or implicitly specified by being identified at the time the asset is made available to the Company;
- b) The Company has the right to obtain substantially all of the economic benefits from use of the identified asset throughout the period of use, considering its rights within the defined scope of the contract; and
- c) The Company has the right to direct the use of the identified asset throughout the period of use. The Company assess whether it has the right to direct 'how and for what purpose' the asset is used throughout the period of use.

Measurement and recognition of leases as a lessee

At lease commencement date, the Company recognizes a right-of-use asset and a lease liability on the balance sheet. The Company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Company also assesses the right-of-use asset for impairment when such indicators exist.

At the commencement date, the Company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available. If the interest rate implicit in the lease is not readily available, the Company discounts using the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed), variable payments based on an index or rate, amounts expected to be payable under a residual value guarantee and payments arising from options reasonably certain to be exercised.

Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is remeasured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is remeasured, the corresponding adjustment is reflected in the right-of-use asset, or profit and loss if the right-of-use asset is already reduced to zero.

The Company has elected to account for short-term leases and leases of low-value assets using the practical expedients. Instead of recognizing a right-of-use asset and lease liability, the payments in relation to these are recognized as an expense in profit or loss on a straight-line basis over the lease term. On the statement of financial position, right-of-use assets have been included under non-current assets and lease liabilities have been included under current and non-current liabilities.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has not entered into any off-balance sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Key management personnel are the directors and officers of the Company. Management compensation transactions for the year ended June 30, 2020 and 2019 is summarized as follows:

	2020	2019
Management fees	\$ 728,265	\$ 424,473
Share-based payments	3,131,373	2,032,955
Total	\$ 3,859,638	\$ 2,457,428

As at June 30, 2020, \$647,083 (2019 - \$596,847) is owed to directors and officers of the Company for unpaid fees and expenses paid on behalf of the Company.

During the year ended June 30, 2020, the Company paid USD\$240,000 (2019 - USD\$120,000) included in management fees to the CEO and Director of the Company pursuant to CEO and director services provided.

During the year ended June 30, 2020, the Company paid \$130,000 included in management fees to the CFO of the Company pursuant to CFO services provided. During the year ended June 30, 2019, the Company paid \$100,000 to the previous CFO for services provided, which is included in management fees.

During the year ended June 30, 2020, the Company paid \$195,150 (2019 - \$137,500) included in management fees to a director of the Company pursuant to director services provided.

During the year ended June 30, 2020, the Company paid \$52,363 (2019 - \$nil) included in management fees to a director of the Company pursuant to director services provided.

During the year ended June 30, 2020, the Company paid \$36,000 (2019 - \$37,500) included in consulting fees to the Corporate Secretary and Director and of the Company pursuant to corporate secretary and director services provided.

During the year ended June 30, 2020, the Company issued 2,350,000 RSUs to directors and officers of the Company with a fair value of \$2,078,591. See Note 14. During the year ended June 30, 2020, the Company recognized share-based payments of \$1,616,682 pertaining to the RSUs, which is included in the consolidation statements of net loss and comprehensive loss.

During the year ended June 30, 2020, the Company settled a convertible debenture held by a director of the Company with a principal amount of \$1,000,000, accrued interest of \$91,778 and an early settlement penalty of \$50,000. The convertible debt had a carrying value of \$789,431 and was settled with 3,743,534 common shares of the Company with a fair value of \$2,957,392 resulting in a loss on debt settlement of \$2,167,960 (see Note 12 and 14).

On Jan 21, 2020, \$239,742 an outstanding payable to the company owned by the director was settled through the issuance of 786,040 units with a fair value of \$620,972. There was a loss of \$381,230 on the settlement. Each unit comprises of one common share and one common share purchase warrant exercisable at a price of \$0.405 for a period of 24 months.

FOURTH QUARTER

The table below reflects selected quarterly information for the three months to June 30, 2020 compared to the comparative period of the previous fiscal period taking into effect continuing operations only:

	Quarter Ended		Quarter Ended	
	June 30, 2020		June 30, 2019	
Total Revenue	\$	3,919,025	\$	4,051,471
Net Loss	\$	(6,599,348)	\$	(19,028,079)
Basic and diluted net loss per share	\$	(0.99)	\$	(2.30)

During the quarter ended June 30, 2020, the Company had revenues of \$3,919,025 compared to \$4,051,471 for the same period end June 30, 2019 for a decrease of \$132,446. Although revenues is fairly consistent, the Company notes that it had moved away from bulk CBD sales and sales of oil in California which accounted for nearly half of the revenues in the comparable period. In the current year, the revenues are entirely from flower, manufactured products and dispensary sales in Puerto Rico.

Operating loss from continuing operations for the quarter ended June 30, 2020 was \$7,026,208 compared to \$19,028,079 for the same period ended June 30, 2019. The decrease in operating losses primarily due to the expense of the acquisition of La Fina, resulting in a one-time expense of \$10,305,740 and the adjustment to the investment in GSRX of \$2,646,285. Revenues were consistent comparatively; however, the Company shifted away from low margin bulk sales to higher-margin cultivation, manufacturing and retail sales.

See summary of quarterly results for further information regarding quarterly disclosures.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

Financial Instruments

The classification of the financial instruments as well as their carrying values are shown in the table below:

	Category	June 30, 2020	June 30, 2019
Financial Assets			
Cash	Amortized cost	\$ 1,044,585	\$ 641,583
Amounts receivable	Amortized cost	752,668	2,392,559
Investment in GSRX	Fair value through profit and loss	-	14,497,777
Total Financial Assets		\$ 1,797,253	\$ 17,531,919
Financial Liabilities			
Accounts payable and accrued liabilities	Amortized cost	\$ 6,051,158	\$ 2,488,824
Acquisitions payable	Amortized cost	-	1,308,700
Notes payable	Amortized cost	-	838,366
Derivative liability	Fair value through profit and loss	-	3,152,490
Unearned revenue	Amortized cost	-	235,639
Convertible debt	Amortized cost	1,063,562	-
Total financial liabilities		\$ 7,114,720	\$ 8,024,019

The Company has classified fair value measurements of its financial instruments using a fair value hierarchy that reflects the significance of inputs used in making the measurements as follows:

Level 1: Valuation based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2: Valuations based on directly or indirectly observable inputs in active markets for similar assets or liabilities, other than Level 1 prices, such as quoted interest or currency exchange rates; and

Level 3: Valuations based on significant inputs that are not derived from observable market data, such as discounted cash flow methodologies based on internal cash flow forecasts.

At June 30, 2020 and June 30, 2019, cash is measured using Level 1 inputs. Derivative liability is measured using Level 2 inputs. During the year ended June 30, 2020 and June 30, 2019, there were no transfers between Level 1 and Level 2 fair value measurements and there were no transfers in and out of Level 3 fair value measurements.

The fair values of the Company's financial assets and liabilities approximate their carrying amounts. The carrying value of receivables and accounts payable, acquisitions payable and accrued liabilities approximate their fair value because of the short-term nature of these instruments. The carrying value of loans payable approximate their carrying value based on currently available borrowing rates for debt on similar terms, credit risk and maturities. The fair value of convertible debt is measured using a discount factor of 15% which approximates the borrowing rate that the Company would get for debt without a conversion feature and warrants.

Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair values.

Financial risk factors

The Company's risk exposures and the impact on the Company's financial instruments are summarized below:

Liquidity risk

Liquidity risk is the risk that the Company is not able to meet its financial obligations as they fall due. As at June 30, 2020, the Company has a working capital deficit of \$3,267,725 (June 30, 2019 - \$204,230) and total lease liabilities of \$3,410,542 (June 30, 2019 - \$nil). The Company may seek additional financing through debt or equity offerings, but there can be no assurance that such financing will be available on terms acceptable to the Company or at all. Any equity offering will result in dilution to the ownership interests of the Company's shareholders and may result in dilution to the value of such interests. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As at June 30, 2020, the Company had cash of \$1,044,585 (June 30, 2019 - \$641,583), accounts payable and accrued liabilities of \$6,051,158 (June 30, 2019 - \$2,488,824), notes payable of \$nil (June 30, 2019 - \$838,366), acquisition payable of \$nil (June 30, 2019 - \$1,308,700), and convertible debt of \$1,063,562 (June 30, 2019 - \$nil).

There can be no assurance the Company will be able to obtain required financing in the future on acceptable terms. The Company anticipates it will need additional capital in the future to finance on-going expansion of its subsidiaries, such capital to be derived from the completion of other equity and debt financings. The Company has limited financial resources, is currently generating net losses from operations, and has no assurance that additional funding will be available to it for future development of its business. The ability of the Company to arrange additional financing in the future will depend, in part, on the prevailing capital market conditions. In recent years, the securities markets have experienced wide fluctuations in price which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continual fluctuations in price will not occur. Any quoted market for the common shares may be subject to market trends generally, notwithstanding any potential success of the Company in creating revenue, cash flows or earnings.

Credit risk

Credit risk is the risk of potential loss to the Company if the counterparty to a financial instrument fails to meet its contractual obligations. The Company's credit risk is primarily attributable to its liquid financial assets including cash and accounts receivable.

The Company limits exposure to credit risk on liquid financial assets through maintaining its cash with high-credit quality financial institutions. Receivables primarily consist of trade receivables due from merchant accounts.

The Company's maximum exposure to credit risk related to certain financial instruments as identified below, approximate the carrying value of these assets on the Company's consolidated statements of financial position.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, foreign exchange rates, and equity prices. The Company does not have a practice of trading derivatives.

a) Interest rate risk

The Company's financial assets exposed to interest rate risk consist of cash. The Company's policy will be to invest excess cash in investment-grade short-term deposit certificates issued by its banking institutions. The Company is satisfied with the credit ratings of its banks. As at June 30, 2020, the Company did not have any investments in investment-grade short-term deposit certificates.

b) Foreign currency risk

The Company's foreign exchange risk arises from transactions denominated in other currencies.

Use of Estimates and Judgements

The assumption that the Company will be able to continue as a going concern is subject to critical judgments by management with respect to assumptions surrounding the short and long-term operating budget, expected profitability, investing and financing activities and management's strategic planning. Should those judgments prove to be inaccurate, management's continued use of the going concern assumption could be inappropriate.

Going concern

The assessment of the Company's ongoing viability as an operating entity and determination of the related disclosures require significant judgment.

Business combinations

Judgment is used when determining whether an acquisition is a business combination or an asset acquisition. Judgment is also used in measuring the fair value of equity instruments issued as consideration for a business combination, and in allocating the fair value of consideration paid to the assets acquired and liabilities assumed.

The Company measures all assets acquired and liabilities assumed at their acquisition-date fair values. Non-controlling interests in the acquiree are measured on the basis of the non-controlling interests' proportionate share of this equity in the acquiree's identifiable net assets. The excess of the aggregate of the consideration transferred and the amount of any non-controlling interest in the acquiree over the net assets of the acquisition-date amount of the identifiable assets acquired and the liabilities assumed, is recognized as goodwill as of the acquisition date.

Functional currency

Determination of an entity's functional currency involves judgment taking into account the transactions, events, and conditions relevant to the entity. Determination of functional currency involves evaluating evidence about the primary economic environment in which the entity operates and is re-evaluated when facts and circumstances indicate that conditions have changed.

Revenues - gross vs net

Determination of whether the Company is the agent or principal in a transaction involves judgment taking into account whether the Company accepts inventory risk, responsibility for fulfilling the purchaser and exercises price discretion.

Collectability of amounts receivable

The Company monitors its exposure for credit losses on its customer and related party receivable balances and the creditworthiness of the customers and related parties on an ongoing basis and records related allowances for doubtful accounts. Allowances are estimated based upon specific customer and related party balances, where a risk of default is identified, and also include a provision for non-customer specific defaults based upon historical experience and aging of accounts. As of June 30, 2020, the Company recorded an allowance for doubtful accounts of \$391,978 (2019 - \$336,296). If circumstances related to specific customers and related parties change, estimates of the recoverability of amounts receivable could also change.

Financial instruments

The determination of categories of financial assets and liabilities has been identified as an accounting policy which involves judgments or assessments made by management.

The identification of convertible note component is based on interpretations of the substance of the contractual arrangement and therefore requires judgement from management. The separation of components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of fair value of the liability is also based on several assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

Biological assets

Determination of the fair value of biological assets requires the Company to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, sales prices, wastage and expected yields of the cannabis plant. In determining final inventory values, the Company estimates spoiled or expired inventory in determining net realizable value.

The Company's estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the gain or loss on biological assets in future periods.

Inventory

The Company estimates the net realizable value of inventory taking into account the most reliable evidence available at each reporting date.

Share-based payments

Share-based payments, as measured with respect to stock options granted are estimated by reference to the Black-Scholes pricing model.

Income Taxes

The determination of income tax is inherently complex and requires making certain estimates and assumptions about future events. While income tax filings are subject to audits and reassessments, the Company has adequately provided for all income tax obligations. However, changes in facts and circumstances as a result of income tax audits, reassessments, jurisprudence and any new legislation may result in an increase or decrease in the provision for income taxes.

Valuation of investment in GSRX

Management exercises judgment on the valuation of the investment in GSRX with reference to the valuation of the consideration received, and if appropriate, the valuation of the share consideration granted. On August 28, 2019, the Company completed an acquisition of control now includes this investment as a component of the purchase price of GSRX.

Valuation of equity consideration granted

The valuation of share consideration granted involves management judgment in determining valuation of the share consideration granted. Judgment is exercised in the reliability of the fair value of consideration received.

The fair value of equity instruments is subject to the limitations of the Black-Scholes option pricing model, as well as other pricing models that incorporate market data and involves uncertainty in estimates used by management in the assumptions. Because option pricing models require inputs of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate

Estimated useful lives, impairment considerations and amortization of tangible assets, intangible assets, and goodwill

Amortization of tangible assets and intangible assets is dependent upon estimates of useful lives based on management's judgment.

Goodwill impairment testing requires management to make critical estimates within the impairment testing model. On an annual basis, the Company tests whether goodwill is impaired.

Impairment of tangible and intangible assets with limited lives are affected by judgments about impairment indicators and estimates used to measure impairment losses where necessary.

The recoverable value of goodwill and tangible and intangible assets is determined using discounted cash flow models, which incorporate assumptions about future events including future cash flows, growth rates and discount rates.

SUBSEQUENT EVENTS

Subsequent to June 30, 2020, the Company completed the following transactions:

- a) On July 3, 2020, the Company paid finder's fees totaling \$35,000 and issued an aggregate of 70,000 finder's warrants to an arm's-length party. Each Finder's Warrant is exercisable into one common share in the capital of the Company until July 3, 2022;
- b) On July 3, 2020, the Company closed the Third Tranche of 2,542,800 units and completed a private placement of a total of 5,235,300 units;
- c) On July 10, 2020, the Company entered into a marketing contract for a term of 90 days for consideration of US \$400,000;
- d) Effective July 22, 2020, the Company's common shares are listed in US dollars, under the symbols CSE:CSI.u, OTC:CADMF and FRA:CWAA;
- e) On August 7, 2020, the Puerto Rico Court of Appeals ruled in favour of the DHPR, which reverses the previous judgement in the Company's favour. The Company's licenses are still operational;
- f) On August 8, 2020, the Company settled liabilities of \$470,843 and US\$24,000 through the issuance of 692,416 units and 38,307 shares;
- g) On September 2, 2020, the DHPR extended the Company's Puerto Rico licenses for an additional 60 days;
- h) On September 11, 2020, 125,000 of Restricted Share Rights were converted into common shares;
- i) On September 28, 2020, the DHPR commenced a review of certain files made by the Company's Puerto Rican subsidiaries; and
- j) Between August 4, 2020 and the date of this MD&A, 1,646,191 warrants were exercised raising proceeds of \$666,707.

PROPOSED TRANSACTIONS

There are no proposed transactions.

DISCLOSURE OF OUTSTANDING SHARE DATA

Common Shares

Common shares issued and outstanding as at October 28, 2020, are 38,935,721 (June 30, 2020 – 33,791,693) of which 729,817 common shares are classified as held internally and deducted from the statement of changes in shareholders equity. As at October 28, 2020, the Company held 688,072 common shares in escrow.

Share Purchase Warrants

As at October 28, 2020, the Company had 24,833,594 (June 30, 2020 – 21,528,378) share purchase warrants outstanding with expiry dates as follows:

Expiry date	Warrants	Exercise Price	
December 4, 2020	160,000	\$	15.00
December 21, 2023	31,250		15.00
October 3, 2021	77,651		15.00
December 20, 2023	120,010		15.00
January 21, 2024	38,460		24.50
March 1, 2024	150,000		25.00
May 30, 2024	18,918		25.00
May 30, 2024	37,837		25.00
June 13, 2024	5,405		25.00
January 21, 2022	16,393,444		0.405
January 23, 2022	570,192		0.70
January 23, 2022	1,232,711		1.12
May 19, 2022	1,420,000		1.00
May 20, 2022	1,272,500		1.00
July 3, 2022	2,612,800		1.00
July 24, 2022	692,416		0.85
Balance, October 28, 2020	24,833,594	\$	2.33

Common shares issued and outstanding as at October 28, 2020, are 38,207,221 (June 30, 2020 – 33,891,694). 729,817 common shares of the Company are classified as held internally and deducted from the statement of changes in shareholders' equity. As at October 28, 2020, the Company held 688,072 common shares in escrow.

Stock Options

As at October 28, 2020, the Company had 2,295,000 (June 30, 2020 – 2,295,000) options outstanding with expiry dates as follows:

Expiry date	Outstanding and exercisable			Remaining contractual life (years)
	Options	Exercise price		
January 12, 2025	2,295,000	\$	0.90	4.53
Balance, June 30, 2020	2,295,000	\$	0.90	4.53

As at October 28, 2020, the Company had 125,000 (June 30, 2020 – 2,500,000) restricted share units that convert to a common share of the Company on July 21, 2020.

RISK FACTORS

Much of the information included in this report includes or is based upon estimates, projections or other forward-looking statements. Such forward-looking statements include any projections or estimates made by the Company and its management in connection with the Company's business operations. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect the Company's current judgment regarding the direction of its business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions, or other future performance suggested herein. Except as required by law, the Company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of such statements.

Such estimates, projections or other forward-looking statements involve various risks and uncertainties as outlined below. The Company cautions readers of this report that important factors in some cases have affected and, in the future, could materially affect actual results and cause actual results to differ materially from the results expressed in any such estimates, projections or other forward-looking statements. In evaluating the Company, its business and any investment in its business, readers should carefully consider the factors set out below. However, the risks and uncertainties set out in this MD&A are not exhaustive. New risk factors may emerge from time to time and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company's business performance, condition, operations or strategies and plans.

Additional financing

There is no guarantee that the Company will be able to achieve its business objectives. The continued development of the Company may require additional financing. The failure to raise such capital could result in the delay or indefinite postponement of current business objectives or the Company going out of business. There can be no assurance that additional capital or other types of financing will be available if needed or that, if available, the terms of such financing will be favourable to the Company. If additional funds are raised through issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences and privileges superior to those of holders of common shares of the Company. In addition, from time to time, the Company may enter into transactions to acquire assets or the shares of other corporations. These transactions may be financed wholly or partially with debt, which may temporarily increase the Company's debt levels above industry standards. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions.

The Company will require additional financing to fund its operations to the point where it is generating positive cash flows. Continued negative cash flow may restrict the Company's ability to pursue its business objectives.

Commercial banks, private equity firms and venture capital firms have approached the cannabis industry cautiously to date. However, there are increasing numbers of high net worth individuals and family offices that have made meaningful investments in companies and projects similar to the Company's projects. Although there has been an increase in the amount of private financing available over the last several years, there is neither a broad nor deep pool of institutional capital that is available to cannabis license holders and license applicants. There can be no assurance that any such financing will be available to the Company when needed or on terms which are acceptable. The Company's inability to raise financing to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability.

Key Personnel

Another risk associated with the production and sale of recreational cannabis is the loss of important staff members. The Company is currently in good standing with all high-level employees and believes that with well managed practices will remain in good standing. The success of the Company will be dependent upon the ability, expertise, judgment, discretion and good faith of its senior management and key personnel. While employment agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on the Company's business, operating results or financial condition.

The Company's directors and officers are engaged in other business activities and accordingly may not devote sufficient time to the Company's business affairs, which may affect its ability to conduct operations and generate revenues.

The Company's directors and officers are involved in other business activities. As a result of their other business endeavours, the directors and officers may not be able to devote sufficient time to the Company's business affairs, which may negatively affect its ability to conduct its ongoing operations and its ability to generate revenues. In addition, the management of the Company may be periodically interrupted or delayed as a result of its officers' other business interests.

Certain directors or officers of the Company are also directors, officers, shareholders and/or promoters of other reporting and non-reporting issuers. Such associations may give rise to conflicts of interest from time to time. The

directors and officers of the Company are required by law to act honestly and in good faith with a view to the best interests of the Company and to disclose any interest which they may have in any project or opportunity of the Company. If a conflict of interest arises at a meeting of the Board of Directors, any director in a conflict will disclose his interest and abstain from voting on such matter. Conflicts of interest, if any, will be subject to, and will be resolved in accordance with, the procedures and remedies under the *Business Corporations Act* (British Columbia).

Dependence on Suppliers and Skilled Labour

The ability of the Company to compete and grow will be dependent on it having access, at a reasonable cost and in a timely manner, to skilled labour, equipment, parts and components. No assurances can be given that the Company will be successful in maintaining its required supply of skilled labour, equipment, parts and components. This could have an adverse effect on the financial results of the Company.

Reliance on Key Inputs

The Company's business is dependent on a number of key inputs including raw materials and supplies relating to its growing operations including electricity, water, and other utilities. Any significant interruption or negative change in the availability or pricing of the supply chain for these key inputs could materially impact the Company's operations, financial condition, and operating results.

The Company's Products

As a relatively new industry, there are not many established players in the recreational cannabis industry whose business model the Company can follow or build on the success of. Similarly, there is no information about comparable companies available for potential investors to review in making a decision about whether to invest in the Company.

Shareholders and investors should further consider, among other factors, the Company's prospects for success in light of the risks and uncertainties encountered by companies that, like the Company, are in their early stages. For example, unanticipated expenses and problems or technical difficulties may occur, and they may result in material delays in the operation of The Company's business. The Company may not successfully address these risks and uncertainties or successfully implement its operating strategies. If the Company fails to do so, it could materially harm the Company's business to the point of having to cease operations and could impair the value of the Company's common shares to the point investors may lose their entire investment.

The Company has committed, and expects to continue to commit, significant resources and capital to develop and market existing products and new products and services. These products are relatively untested, and the Company cannot assure shareholders and investors that it will achieve market acceptance for these products, or other new products and services that The Company may offer in the future. Moreover, these and other new products and services may be subject to significant competition with offerings by new and existing competitors in the business. In addition, new products and services may pose a variety of challenges and require the Company to attract additional qualified employees. The failure to successfully develop and market these new products and services could seriously harm the Company's business, financial condition and results of operations.

Product Recalls

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. If any of the Company's products are recalled due to an alleged product defect or for any other reason, the Company could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. The Company may lose a significant amount of sales and may not be able to replace those sales at an acceptable margin or at all. In addition, a product recall may require significant management attention. Although the Company has detailed procedures in place for testing its products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits. Additionally, if one of the Company's significant brands were subject to recall, the image of that brand and the Company could be harmed. A recall for any of the foregoing reasons could lead to decreased demand for the

Company's products and could have a material adverse effect on the results of operations and financial condition of the Company. Additionally, product recalls may lead to increased scrutiny of the Company's operations by the U.S. Food and Drug Administration, the California or Puerto Rico Department of Public Health, or other regulatory agencies, requiring further management attention and potential legal fees and other expenses.

Product Liability

The Company faces an inherent risk of exposure to product liability claims, regulatory action and litigation if its products are alleged to have caused significant loss or injury. In addition, the sale of the Company's products would involve the risk of injury to consumers due to tampering by unauthorized third parties or product contamination. Previously unknown adverse reactions resulting from human consumption of the Company's products alone or in combination with other medications or substances could occur. The Company may be subject to various product liability claims, including, among others, that the Company's products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation with its clients and consumers generally, and could have a material adverse effect on the results of operations and financial condition of the Company. There can be no assurances that the Company will be able to obtain or maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could prevent or inhibit the commercialization of the Company's potential products.

Liquidity

The Company cannot predict at what prices the Company will trade and there can be no assurance that an active trading market will develop or be sustained. There is a significant liquidity risk associated with an investment in the Company.

Sales of Substantial Amounts of the Shares May Have an Adverse Effect on the Market Price of the Shares

Sales of substantial amounts of the common shares of the Company, or the availability of such securities for sale, could adversely affect the prevailing market prices for the common shares. A decline in the market prices of the common shares of the Company could impair the Company's ability to raise additional capital through the sale of securities should it desire to do so.

Volatile Market Price for the Shares

The market price for the common shares of the Company may be volatile and subject to wide fluctuations in response to numerous factors, many of which will be beyond the Company's control, including, but not limited to the following:

- actual or anticipated fluctuations in the Company's quarterly results of operations;
- recommendations by securities research analysts;
- changes in the economic performance or market valuations of companies in the industry in which the Company will operate;
- addition or departure of the Company's executive officers and other key personnel;
- release or expiration of transfer restrictions on outstanding common shares of the Company;
- sales or perceived sales of additional common shares of the Company;
- operating and financial performance that vary from the expectations of management, securities analysts and investors;
- regulatory changes affecting the Company's industry generally and its business and operations both domestically and abroad;
- announcements of developments and other material events by the Company or its competitors;
- fluctuations to the costs of vital production materials and services;
- changes in global financial markets and global economies and general market conditions, such as interest rates and pharmaceutical product price volatility;
- significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving the Company or its competitors;

- operating and share price performance of other companies that investors deem comparable to the Company or from a lack of market comparable companies; and
- news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in the Company's industry or target markets.

Financial markets have recently experienced significant price and volume fluctuations that have particularly affected the market prices of equity securities of companies and that have often been unrelated to the operating performance, underlying asset values or prospects of such companies. Accordingly, the market price of the shares of the Company may decline even if the Company's operating results, underlying asset values or prospects have not changed. Additionally, these factors, as well as other related factors, may cause decreases in asset values that are deemed to be other than temporary, which may result in impairment losses. There can be no assurance that continuing fluctuations in price and volume will not occur. If such increased levels of volatility and market turmoil continue, the Company's operations could be adversely impacted, and the trading price of the shares of the Company may be materially adversely affected.

The Business is Dependent on Laws Pertaining to the Marijuana Industry

Continued development of the marijuana industry is dependent upon continued legislative authorization of the use and cultivation of marijuana at the Federal and State level. Any number of factors could slow or halt progress in this area. Further, progress, while encouraging, is not assured. While there may be ample public support for legislative action, numerous factors impact the legislative process. Any one of these factors could slow or halt use of marijuana, which would negatively impact the proposed business.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, its holding (directly or indirectly) of cannabis licenses in the United States (including Puerto Rico), the listing of its securities on various stock exchanges, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial.

The Company Will Be an Entrant Engaging in a New Industry

The recreational cannabis industry is fairly new. There can be no assurance that an active and liquid market for common shares of the Company will develop and shareholders may find it difficult to resell their shares. Accordingly, no assurance can be given that the Company will be successful in the long term.

Changes in Laws

Changes to any of the laws, rules, regulations or policies to which the Company is subject could have a significant impact on the Company's business. There can be no assurance that the Company will be able to comply with any future laws, rules, regulations and policies. Failure by the Company to comply with applicable laws, rules, regulations and policies may subject it to civil or regulatory proceedings, including fines or injunctions, which may have a material adverse effect on the Company's business, financial condition, liquidity and results of operations. In addition, compliance with any future laws, rules, regulations and policies could negatively impact the Company's profitability and have a material adverse effect on its business, financial condition, liquidity and results of operations.

Unfavourable Publicity or Consumer Perception

Proposed management of the Company believes the recreational cannabis industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of the recreational cannabis produced. Consumer perception of the Company's proposed products may be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of recreational cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favourable to the recreational cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media

attention or other publicity that are perceived as less favourable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company's proposed products and the business, results of operations, financial condition and cash flows of the Company. The Company's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for the Company's proposed products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of recreational cannabis in general, or the Company's proposed products specifically, or associating the consumption of recreational cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products appropriately or as directed.

The Company has Limited Operating History

The Company has limited operating history and may not succeed. The Company is subject to all risks inherent in a developing business enterprise. The Company's likelihood of continued success must be considered in light of the problems, expenses, difficulties, undercapitalization, cash shortages, limitations with respect to personnel, financial and other resources, lack of revenues, complications, and delays frequently encountered in connection with the competitive and regulatory environment in which it operates. For example, the adult use marijuana industry is a relatively new industry which, as a whole may not succeed, particularly should the federal government of the United States decide to prosecute various parties under federal law. There is no assurance that the Company will be successful in achieving a return on shareholders' investment and the likelihood of success must be considered in light of the early stage of operations.

Losses

The Company has incurred losses in recent periods. The Company may not be able to achieve or maintain profitability and may continue to incur significant losses in the future. In addition, the Company expects to continue to increase operating expenses as it implements initiatives to continue to grow its business. If the Company's revenues do not increase to offset these expected increases in costs and operating expenses, it will not be profitable.

Insurance and Uninsured Risks

The Company's business is subject to a number of risks and hazards generally, including adverse environmental conditions, accidents, labour disputes and changes in the regulatory environment. Such occurrences could result in damage to assets, personal injury or death, environmental damage, delays in operations, monetary losses and possible legal liability.

Although the Company intends to continue to maintain insurance to protect against certain risks in such amounts as it considers to be reasonable, its insurance will not cover all the potential risks associated with its operations. The Company may also be unable to maintain insurance to cover these risks at economically feasible premiums. Insurance coverage may not continue to be available or may not be adequate to cover any resulting liability. Moreover, insurance against risks such as environmental pollution or other hazards encountered in the operations of the Company is not generally available on acceptable terms. The Company might also become subject to liability for pollution or other hazards which may not be insured against or which the Company may elect not to insure against because of premium costs or other reasons. Losses from these events may cause the Company to incur significant costs that could have a material adverse effect upon its financial performance and results of operations.

Management of Growth

The Company may be subject to growth-related risks including capacity constraints and pressure on its internal systems and controls. The ability of the Company to manage growth effectively will require it to continue to implement and improve its operational and financial systems and to expand, train and manage its employee base. The inability of the Company to deal with this growth may have a material adverse effect on the Company's business, financial condition, results of operations and prospects.

Internal Controls

Effective internal controls are necessary for the Company to provide reliable financial reports and to help prevent fraud. Although the Company will undertake a number of procedures and will implement a number of safeguards, in each case, in order to help ensure the reliability of its financial reports, including those imposed on the Company under Canadian securities law, the Company cannot be certain that such measures will ensure that the Company will maintain adequate control over financial processes and reporting. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company's results of operations or cause it to fail to meet its reporting obligations. If the Company or its auditors discover a material weakness, the disclosure of that fact, even if quickly remedied, could reduce the market's confidence in the Company's consolidated financial statements and materially adversely affect the trading price of the Company's shares.

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company such a decision could adversely affect the Company's ability to continue operating and the market price for Reporting Issuer's shares and could use significant resources. Even if the Company is involved in litigation and wins, litigation can redirect significant Reporting Issuer resources.

Risks Inherent in an Agricultural Business

The Company's business involves the growing of recreational cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although all such growing is expected to be completed indoors under climate-controlled conditions, there can be no assurance that natural elements will not have a material adverse effect on any such future production.

Shelf Life of Inventory

The Company holds finished goods in inventory, including dried cannabis and oil products with a shelf life. The Company has a typical inventory turnover that varies and as a result, inventory may reach its expiration date and no longer be available for sale. As a result, inventory may have to be written down and could have a material adverse effect on the Company's business, financial condition, and results of operations.

Dividends

To date, the Company has not paid any dividends on its outstanding securities and the Company does not expect to do so in the foreseeable future. Any decision to pay dividends on Company's shares will be made by the Board of Directors.

Speculative investment

An investment in the Company's common shares is highly speculative and subject to a number of risks and uncertainties. Only those persons who can bear the risk of the entire loss of their investment should participate. An investor should carefully consider the risks described above and the other information filed with the Canadian securities regulators before investing in the Company's common shares. The risks described are not the only ones faced. Additional risks that the Company currently believes are immaterial may become important factors that affect the Company's business. If any of these risks occur, or if others occur, the Company's business, operating results and financial condition could be seriously harmed and investors may lose all of their investment.

ADDITIONAL INFORMATION

Additional information about the Company is available on SEDAR at <http://www.sedar.com>.

BOARD APPROVAL

The board of directors of the Company has approved this MD&A.